Bill Sorabella

Cooley advised Movable Ink, an artificial intelligence-powered personalized content platform, on its definitive agreement to be acquired by STG. The transaction is expected to close in July 2025.

Cooley advised Avid Bioservices (Nasdaq: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, on its definitive merger agreement to be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners in an all-cash transaction valued at approximately $1.1 billion.

Cooley advised Contentsquare, a global leader in digital experience analytics, on its definitive agreement to acquire Heap, an analytics platform.

Cooley advised Tourmaline Bio, a late-stage clinical biotechnology company, on its merger agreement with Talaris Therapeutics, including a concurrent private placement.

Cooley advised Amryt Pharma, a Dublin, Ireland-based commercial-stage biopharmaceutical company, on its definitive agreement to be acquired by Chiesi Farmaceutici, a Parma, Italy-based research-focused biopharmaceuticals and healthcare group, in a $1.48 billion cash and contingent value right (CVR) transaction. Partners Bill Sorabella, Claire Keast-Butler and Bill Roegge led the joint US and UK Cooley team advising Amryt.